Evidence map›Paper›PMID 31853537›Full record

ArticleAmerican journal of hypertension2020

Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.

Oyunbileg Magvanjav, Rhonda M Cooper-Dehoff, Caitrin W McDonough, Yan Gong, William R Hogan, Julie A Johnson

Abstract read
In one paragraph

Article in American journal of hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Factors associated with non-treatment of hypertension and gender differences at baseline in the ELSA-Brasil cohort.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oyunbileg MagvanjavDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Rhonda M Cooper-DehoffDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Yan GongDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
William R HoganDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, Gainesville, Florida, USA.
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Together: Transforming and Translating Discovery to Improve HealthKL2TR001429 · NCATS · UNIVERSITY OF FLORIDA · PI GUIRGIS, FAHEEM W, LEEUWENBURGH, CHRISTIAAN · 2015 to 2023
$5.5M
REnal TrAIning & reteNtion (RETAIN) ProgramT32DK104721 · NIDDK · UNIVERSITY OF FLORIDA · PI SEGAL, MARK S., WOOD, CHARLES E · 2015 to 2019
$1.6M
INTEGRATIVE DATA APPROACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTIONK01HL141690 · NHLBI · UNIVERSITY OF FLORIDA · PI MCDONOUGH, CAITRIN W · 2018 to 2021
$486k
NCATS NIH HHS KL2 TR001429NCATS NIH HHS UL1 TR001427NHLBI NIH HHS K01 HL141690NIDDK NIH HHS T32 DK104721
6 · The paper itself

Abstract

backgroundSpecific combinations of two drug classes are recommended in a variety of clinical situations in the management of hypertension. These preferred combinations are based on complimentary blood pressure (BP) lowering mechanisms or benefit for a concomitant disease.

methodsUsing electronic health records (EHRs) data from 27,579 ambulatory hypertensive patients, we investigated antihypertensive therapy prescribing patterns and associations of preferred two drug classes with BP control.

resultsOverall, BP control, defined as BP <140/90 mm Hg, was 65% among treated patients. Preferred dual antihypertensive therapy was prescribed in 55% of patients with uncomplicated hypertension, 49% of patients with diabetes, and 47% of patients with a history of myocardial infarction (MI); these prescribing frequencies of preferred combinations were not explained by worse BP control on those combinations. In fact, we found suggestive evidence of association between prescribing of preferred two drug classes and improved BP control among post-MI (OR: 1.21, 95% CI: 0.99-1.48, P = 0.061) and uncomplicated hypertensive (OR: 1.11, 95% CI: 0.98-1.26, P = 0.089) patients.

conclusionsPrescribing of guideline-recommended antihypertensive drug classes for concomitant diseases is suboptimal and prescribing of preferred/optimized drug class combinations was moderate. We did not find a clear association between the use of optimized drug class combinations and greater BP control. Overall, using EHR data, we identified potential opportunities for re-examining prescribing practices with implications for clinical decision support and healthcare improvement at the community and health system-wide levels.

Indexed as

AdultAgedAntihypertensive AgentsBlood PressureDrug PrescriptionsDrug Therapy, CombinationDrug UtilizationElectronic Health RecordsFemaleHumansHypertensionMaleMiddle AgedPractice Patterns, Physicians'Treatment OutcomeAntihypertensive Agentsantihypertensive agentsblood pressureblood pressure controlcombination therapydrug prescribingelectronic health recordshypertension

Identifiers

PMID31853537
PMCPMC7109351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.